摘要
目的:系统评价胰高血糖素样肽1受体激动剂治疗2型糖尿病的临床疗效。方法:根据PICOS原则制定检索策略,计算机检索MEDLINE、EMBASE、CENTRAL等数据库,检索时限从建库至2018年8月。严格按照纳入排除标准筛选随机双盲对照试验,提取纳入文献的基本信息和结局指标,采用Corchrane偏倚风险评估工具对文献进行方法学质量评价。采用软件STATA14.0对各效应指标进行网状Meta分析,连续性变量用均数差(MD)及95%CI计算,二分类变量用比值比(OR)及95%CI计算。结果:共纳入51篇英文研究,合计22360例患者,涉及19个干预措施。网状Meta分析显示,在疗效方面,索马鲁肽1.0 mg降低糖化血红蛋白、提高HbA1c<7%达标率、降低空腹血糖、减轻体质量、降低收缩压最明显,艾塞那肽10μg降低舒张压最明显。结论:胰高血糖素样肽1受体激动剂治疗2型糖尿病有良好的疗效。
OBJECTIVE OBJECTIVE To systematically evaluate the efficacy of glucagon-like peptide-1 receptor agonists of type 2 diabetes mellitus.METHODS The search strategy was developed according to PICOS principles,and electronic databases such as MEDLINE,EMBASE,and CENTRAL were searched by computer from inception to August 2018.Randomized double-blind controlled trials were screened in strict accordance with the inclusion and exclusion criteria,basic information and outcome measures of the included articles were extracted,and the methodological quality of the articles was evaluated using the Corchrane Risk of Bias Assessment Tool.Reticular meta-analysis was performed for each effect indicator using the software STATA14.0,continuous variables were calculated with mean difference(MD)and 95%CI,and binary variables were calculated with odds ratio(OR)and 95%CI.RESULTS A total of 51 English studies involving 22360 patients and 19 interventions were included in our meta-analysis.Network meta-analysis showed that in terms of efficacy,somalutin 1.0 mg reduced glycosylated hemoglobin,increased HbA1 c<7%compliance rate,reduced fasting blood glucose,reduced body mass,and reduced systolic blood pressure most significantly,and exenatide 10μg reduced diastolic blood pressure most significantly.CONCLUSION Glucagon-like peptide-1 receptor agonists had good efficacy in treating type 2 diabetes mellitus.
作者
张春燕
范玲
谢星星
ZHANG Chun-yan;FAN Ling;XIE Xing-xing(Drug Clinical Trial Institution,the Hospital Affiliated to Southwest Medical University,Sichuan Luzhou 646000,China;Department of Pharmacy,Ya’an People’s Hospital,Sichuan Ya’an 625000,China)
出处
《中国医院药学杂志》
CAS
北大核心
2020年第17期1856-1863,共8页
Chinese Journal of Hospital Pharmacy
基金
西南医科大学科技计划基金资助项目(编号:2017-ZRQN-133)。
